Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis vs on‐demand therapy
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people without inhibitors
1 finding from 1 review
- Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B 2024 · Cochrane Headline outcomes onlyno estimate extracted1 study · 54 participantsModerate